Biofrontera Past Earnings Performance
Past criteria checks 0/6
Biofrontera's earnings have been declining at an average annual rate of -11.3%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 15.7% per year.
Key information
-11.3%
Earnings growth rate
48.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 15.7% |
| Return on equity | n/a |
| Net Margin | -69.4% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Biofrontera makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 33 | -23 | 38 | 0 |
| 31 Dec 23 | 34 | -20 | 38 | 0 |
| 30 Sep 23 | 34 | -26 | 38 | 0 |
| 30 Jun 23 | 29 | -23 | 36 | 0 |
| 31 Mar 23 | 28 | -14 | 36 | 0 |
| 31 Dec 22 | 29 | -1 | 35 | 0 |
| 30 Sep 22 | 28 | -12 | 24 | 0 |
| 30 Jun 22 | 28 | -26 | 33 | 0 |
| 31 Mar 22 | 29 | -29 | 29 | 0 |
| 31 Dec 21 | 24 | -38 | 26 | 0 |
| 30 Sep 21 | 24 | -23 | 32 | 0 |
| 30 Jun 21 | 22 | -10 | 19 | 0 |
| 31 Mar 21 | 19 | -10 | 17 | 0 |
| 31 Dec 20 | 19 | -11 | 18 | 0 |
| 31 Dec 19 | 26 | -11 | 28 | 0 |
Quality Earnings: AI10 is currently unprofitable.
Growing Profit Margin: AI10 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AI10 is unprofitable, and losses have increased over the past 5 years at a rate of 11.3% per year.
Accelerating Growth: Unable to compare AI10's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AI10 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Return on Equity
High ROE: AI10's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.